We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
-$140M
Cap. Flow
+$106M
Cap. Flow %
4.61%
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$37.7M
2
DXCM icon
DexCom
DXCM
+$37.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$33.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.7M

Top Sells

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$38.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$27.1M
4
AKRO
Akero Therapeutics
AKRO
+$26.2M
5
REPL icon
Replimune Group
REPL
+$24.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.91%
2 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$203M 8.83%
18,346,861
-1,902,928
-9% -$23.5M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$153M 6.65%
1,913,280
+16,635
+0.9% +$1.31M
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$102M 4.44%
4,205,206
-296,905
-7% -$6.5M
DCPH
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$86.2M 3.74%
5,582,105
+1,988,788
+55% +$33.2M
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$78.2M 3.39%
2,044,389
-588,523
-22% -$26.2M
PLRX icon
6
Pliant Therapeutics
PLRX
$68.7M
$77.8M 3.38%
2,925,648
-952,951
-25% -$27.1M
FATE icon
7
Fate Therapeutics
FATE
$291M
$73.9M 3.2%
12,957,222
– –
KYMR icon
8
Kymera Therapeutics
KYMR
$9.82B
$71.4M 3.1%
2,410,769
-263,068
-10% -$8.48M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.07B
$67.6M 2.93%
1,879,739
-97,712
-5% -$4.22M
REPL icon
10
Replimune Group
REPL
$1.46B
$67.3M 2.92%
3,811,988
-1,019,721
-21% -$24.2M
ZYME icon
11
Zymeworks
ZYME
$2.02B
$54.9M 2.38%
6,067,918
-108,000
-2% -$942K
PEN icon
12
Penumbra
PEN
$12.7B
$52.4M 2.27%
187,992
-33,817
-15% -$8.63M
LIVN icon
13
LivaNova
LIVN
$4.43B
$51.7M 2.24%
1,186,418
+80,009
+7% +$4.05M
BEAM icon
14
Beam Therapeutics
BEAM
$3.03B
$49.4M 2.14%
1,612,094
-158,493
-9% -$6.25M
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.9B
$49M 2.13%
335,159
+16,214
+5% +$2.4M
ARGX icon
16
argenx
ARGX
$64B
$48.6M 2.11%
130,540
-17,977
-12% -$6.65M
XENE icon
17
Xenon Pharmaceuticals
XENE
$5.81B
$47.5M 2.06%
1,325,832
-1,034,582
-44% -$38.2M
IGMS
18
DELISTED
IGM Biosciences
IGMS
$45.8M 1.99%
3,334,355
– –
OSH
19
DELISTED
Oak Street Health, Inc.
OSH
$41.1M 1.78%
1,061,295
-359,322
-25% -$11.6M
CTLT
20
DELISTED
CATALENT, INC.
CTLT
$40.1M 1.74%
+610,304
New +$37.7M
DXCM icon
21
DexCom
DXCM
$34.3B
$39M 1.69%
+336,048
New +$37.6M
SYK icon
22
Stryker
SYK
$127B
$39M 1.69%
136,464
+30,584
+29% +$8.11M
STOK icon
23
Stoke Therapeutics
STOK
$2.04B
$34.5M 1.5%
4,145,396
+3,502,966
+545% +$31.6M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$12.5B
$32.6M 1.41%
+335,170
New +$34.7M
SRPT icon
25
Sarepta Therapeutics
SRPT
$2.2B
$31.9M 1.39%
+231,595
New +$30M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2023 Portfolio in Review

As of Q1 2023, Redmile Group held 80 positions worth $2.3B, down 5.7% from $2.44B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $106M of net new capital in Q1 2023, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was CATALENT, INC.: 610,304 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $38.2M trimmed.

  • Redmile Group's largest Q1 2023 buy was CATALENT, INC.: 610,304 shares worth $40.1M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $33.2M increase.
  • Redmile Group's biggest Q1 2023 reduction was Xenon Pharmaceuticals, cutting an estimated $38.2M.
  • Redmile Group fully exited 1Life Healthcare in Q1 2023, selling an estimated $38.9M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q1 2023.
  • Redmile Group opened 11 new positions and closed 4 in Q1 2023.
  • Redmile Group's portfolio value fell 5.7% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.